Noema Pharma is a Swiss biotech company developing ground-breaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system.
Noema’s research and development is focused on understanding and meeting patient needs using novel therapies.
Noema will achieve its goal through a full partnership with the communities of patients, their families and caregivers and through collaboration with health care providers and policy makers.
Noema focuses on orphan CNS diseases characterized by imbalanced neuronal networks leading to unresolved severe symptoms and significant impact on patient’s overall functioning.
Noema’s experienced and motivated team has a track record of successfully developing and commercializing therapies for conditions affecting the nervous system around the world.